---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-397221"
form_type: "8-K"
ticker: "LXEO"
cik: "0001907108"
company_name: "Lexeo Therapeutics, Inc."
filed_at: "2026-09-22T11:08:41+00:00"
generated_at: "2026-09-22T11:10:28.548670+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Lexeo to acquire Mantle for up to $21.3M; adds FA pipeline and collaborations

## Summary
- Acquisition: $8.3M upfront (cash+equity) plus up to $13M milestones for Mantle; total potential $21.3M; close expected Q3 2026.
- Mantle pipeline adds LX3010 (oral, ~6-pt mFARS improvement, 9x frataxin increase), LX3030, LX3050, LX3070 for FA.
- Collaborations: Weill Cornell (cerebellar sequential dosing), Vivet (VTX-PID option), Apertura (CapX capsid option) to support LX2006.
- LX2006 SUNRISE-FA 2 topline on track for 2H 2027; CLARITY-FA has 22 participants enrolled/imminently enrolling.
- Cash runway into 2028 unchanged; expects to advance one acquired program to clinic and submit an IND in 2027.

## SEC filing metadata
- accession: 0001193125-26-397221
- form_type: 8-K
- ticker: LXEO
- cik: 0001907108
- company_name: Lexeo Therapeutics, Inc.
- filed_at: 2026-09-22T11:08:41+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1907108/000119312526397221/0001193125-26-397221-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1907108/000119312526397221/lxeo-20260916.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-397221
- JSON: https://secwatch.observer/filing/0001193125-26-397221.json
- Plain text: https://secwatch.observer/filing/0001193125-26-397221.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.